PRECIGEN, INC. (PGEN) - Dilution Analysis

10-Q filing | 354.3M shares outstanding

10-K filing | 353.9M shares outstanding

10-Q filing | 353.8M shares outstanding

8-K filing: Holders of Precigen, Inc.'s 8.00% Series A Convertible Perpetual Preferred Stock converted 79,000 shares of Preferred Stock into 54,937,411 shares of common stock of the Company on September 15, 2025, which were delivered on September 17, 2025.

10-Q filing | 296.4M shares outstanding

10-Q filing | 293.9M shares outstanding

10-K filing | 267.7M shares outstanding

8-K filing: Precigen sold 79,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock and warrants to purchase 52,666,669 shares of common stock at an exercise price of $0.75 per share in a private placement for gross proceeds of $79.0 million, which closed on December 30, 2024. ($79.0M proceeds)

10-Q filing | 275.9M shares outstanding

10-Q filing | 252.4M shares outstanding

8-K filing: Precigen, Inc. entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated for a public offering of 35,294,118 shares of Precigen common stock at $0.85 per share, with an option for the underwriters to purchase an additional 5,294,117 shares, resulting in net proceeds of approximately $31.4 million, including the sale of 4,584,821 shares from the underwriters' option. ($34.0M proceeds)

10-Q filing | 249.2M shares outstanding

10-K filing | 244.5M shares outstanding

S-3 filing: Precigen, Inc. is filing a registration statement on Form S-3 relating to the proposed public offering of up to $300,000,000 in aggregate amount of various securities including debt securities, preferred shares, common shares, warrants, subscription rights, stock purchase contracts, and units representing any combination of the foregoing securities.

10-Q filing | 248.5M shares outstanding

10-Q filing | 248.0M shares outstanding

10-Q filing | 255.5M shares outstanding

10-K filing | 252.2M shares outstanding

8-K filing: Precigen, Inc. entered into an underwriting agreement for a public offering of 42,857,143 shares of common stock at $1.75 per share, with an option for the underwriters to purchase an additional 6,428,571 shares, resulting in net proceeds of approximately $71.2 million. ($75.0M proceeds)

10-Q filing | 200.7M shares outstanding

10-Q filing | 200.5M shares outstanding

10-Q filing | 199.6M shares outstanding

10-K filing | 197.8M shares outstanding

10-Q filing | 199.2M shares outstanding

10-Q filing | 199.0M shares outstanding

10-Q filing | 193.5M shares outstanding

10-K filing | 205.7M shares outstanding

10-Q filing | 185.5M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 6,293,402 shares of common stock by selling stockholders, with the company not receiving any proceeds from the sale.

10-Q filing | 172.3M shares outstanding

S-3 filing: Precigen, Inc. files an S-3 to offer and sell up to $500,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, rights, stock purchase contracts, and units from time to time in one or more offerings.

10-Q filing | 163.3M shares outstanding

10-K filing | 160.0M shares outstanding